A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy (SUVN-G3031)

  • End date
    Apr 17, 2023
  • participants needed
  • sponsor
    Suven Life Sciences Limited
Updated on 17 September 2022
body mass index
urine drug screen
experimental drug
sleep disorder
multiple sleep latency test
sleep latency test


This study is of an investigational drug called SUVN-G3031 (Samelisant) as a possible treatment for narcolepsy with cataplexy or narcolepsy without cataplexy. The main purpose of this study is to learn how well the study drug works and how safe the study drug is compared to placebo.


This is a Phase 2, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SUVN-G3031 compared to placebo in participants with narcolepsy with and without cataplexy. Participants will be randomized at a ratio of 1:1:1 to 2 mg SUVN-G3031, 4 mg SUVN-G3031, or placebo. Each participant will receive study drug once daily, in a tablet formulation, for 14 days.

Condition Narcolepsy
Treatment Placebo, SUVN-G3031
Clinical Study IdentifierNCT04072380
SponsorSuven Life Sciences Limited
Last Modified on17 September 2022


Yes No Not Sure

Inclusion Criteria

Ages of 18 to 65 years (adult), inclusive
Have narcolepsy with or without cataplexy (Na-1 or Na-2) based on the International Classification of Sleep Disorders (3rd edition) criteria (new or previously diagnosed)
Have undergone a multiple sleep latency test (MSLT) study showing an MSLT of ≤ 8 minutes
An ESS score of ≥ 12; and mean MWT time of < 12 min
Body mass index ranging from 18 to < 45 kg/m2
Negative urine drug screen
A woman must be either not of childbearing potential or of childbearing potential practicing highly effective methods of birth control
Willingness to complete the study protocol with full compliance with procedures and sign an informed consent form (ICF)

Exclusion Criteria

Habitual wake-up time after 8 AM as assessed by sleep diary, habitual sleep time of < 6 hours, and habitual bedtime past 1 AM as determined by sleep diary entries
Use of any investigational therapy within the 30-day period prior to enrollment
Excessive caffeine (defined as > 600 mg/per day) use at least 1 week prior to baseline assessments and during the course of the trial
Nicotine dependence that has an effect on sleep (eg, a patient who routinely awakens at night to smoke)
Use of concurrent medications prescribed to treat narcolepsy as specified including stimulants, antidepressants and sodium oxybate
Current diagnosis of or past treatment for syndromes known to cause sleep disruption or any other cause of daytime sleepiness
Clinically significant ECG abnormalities
An occupation requiring variable shift work, night shifts, or frequent overnight travel which disrupts sleep patterns
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note